Table 1.
Summary data presenting the investigations for diagnosis of prostate cancer (PCa) for 2005–2016.
| Yr | 2005–2006 | 2007–2008 | 2009–2010 | 2011–2012 | 2013–2014 | 2015–2016 |
|---|---|---|---|---|---|---|
| No. patients | 71 | 160 | 164 | 159 | 143 | 142 |
| Age (± SD) | 67.8 (8.8) | 66.8 (9.4) | 64.6 (9.3) | 63.7 (8.6) | 65.4 (8.3) | 67.9 (8.2) |
| PSA (IQR) | 8.40 (8.90) | 7.12 (6.68) | 6.58 (4.84) | 6.20 (3.75) | 6.40 (5.23) | 6.50 (4.46) |
| IPSS (± SD) | 7 (6) | 10 (8) | 9 (7) | 8 (7) | 7 (6) | 8 (7) |
| T1c (%) | 40 (56.3) | 87 (54.4) | 103 (62.8) | 115 (72.3) | 88 (62.0) | 78 (55.3) |
| ≥ T2 (%) | 31 (43.7) | 72 (45.0) | 61 (37.2) | 44 (27.7) | 54 (38.0) | 63 (44.7) |
| Transperineal biopsy | 1 (1.4) | 1 (0.6) | 1 (0.6) | 0 (0.0) | 2 (1.4) | 3 (2.1) |
| Prebiopsy mpMRI (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 6 (3.8) | 87 (60.8) | 127 (89.4) |
| Low risk (%) | 26 (36.6) | 37 (23.1) | 41 (25.0) | 39 (24.5) | 19 (13.3) | 20 (14.1) |
| Intermediate risk (%) | 29 (40.8) | 86 (53.8) | 87 (53.0) | 74 (46.5) | 79 (55.2) | 72 (50.7) |
| High risk (%) | 16 (22.5) | 36 (22.5) | 36 (22.0) | 46 (28.9) | 45 (31.5) | 49 (34.5) |
IPSS, international prostate symptom score; IQR, interquartile range; mpMRI, multiparametric magnetic resonance imaging; PSA, prostate specific antigen; SD, standard deviation.